We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Enzo Announces Settlement with Sigma-Aldrich in Contract and Patent Litigation

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Enzo Biochem, Inc. has announced that it has reached a settlement with Sigma-Aldrich Corp

Sigma was the defendant in a suit brought by Enzo alleging, among other things, breach of contract and infringement of patents related to the Company's proprietary labeled nucleotide technology.

The settlement agreement followed the recent Markman Hearing ruling by a Federal Court Judge in the Southern District of New York relating to claim terms in eight patents asserted against Sigma. 

"Enzo is pleased to have settled with Sigma-Aldrich on favorable terms. Sigma is the first defendant to settle in the various actions brought by Enzo," the Company said.

"Additional defendants in the various actions include Affymetrix Inc., Roche Diagnostics, Amersham Biosciences, Inc., Perkin Elmer, Inc., Orchid Biosciences, Inc. and Molecular Probes, Inc. We continue to aggressively pursue our claims with respect to the remaining defendants."

Enzo is represented in the litigations by Greenberg Traurig, LLP.